bioAffinity closes $4 million offering, adds pre-funded warrants to prior deal

bioAffinity Technologies Inc. closed its previously announced stock offering on October 9, 2026, according to an 8-K filing. The closing of the sales of these securities under the Purchase Agreement took place on October 9, 2026.¹

The final structure differed slightly from the initial pricing announcement. On October 8, 2026, bioAffinity entered into a securities purchase agreement with an institutional investor to issue and sell 116,545 shares of common stock and pre-funded warrants to purchase up to an aggregate of 536,836 shares of common stock.¹ The offering price was $6.122 per share and $6.115 per pre-funded warrant.¹ For each share or pre-funded warrant purchased, the company concurrently issued in a private placement an unregistered warrant to purchase an aggregate of 980,072 shares, with an exercise price of $6.122 per share, exercisable commencing on the date of stockholder approval for a period of five years.¹

Gross proceeds from the offering were approximately $4 million before fees, and the company intends to use net proceeds for working capital and other general corporate purposes.¹ WallachBeth Capital LLC, the placement agent, is being paid a cash fee equal to 7.5% of gross proceeds, plus a warrant to purchase up to 19,602 shares of common stock at $6.122 per share, and $70,000 for legal and other expenses.¹

The filing also confirmed the related suspension of bioAffinity's at-the-market program. On October 8, 2026, the company suspended the prospectus supplement and related prospectus dated May 27, 2025, tied to its At the Market Issuance Sales Agreement dated May 22, 2025, and said it will not make further sales under that agreement unless a new prospectus supplement is filed.¹ Other than that suspension, the sales agreement remains in full force and effect.¹